Thioredoxin-1 is a novel and attractive therapeutic approach for various diseases including cardiovascular disorders

Cardiovascular and Hematological Disorders - Drug Targets

Volumn 8, Issue 4, 2008, Pages 293-296

  Billiet, Ludivine ^a   Rouis, Mustapha ^a  

^a CNRS   (France)

Author keywords

Antioxidant; Cardiovascular diseases; Inflammation; Oxidative stress; Thioredoxin

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; ASCORBIC ACID; BETA CAROTENE; COLECALCIFEROL; GW 647; GW 929; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; REACTIVE OXYGEN METABOLITE; RECOMBINANT PROTEIN; RECOMBINANT THIOREDOXIN 1; THIOREDOXIN 1; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; THIOREDOXIN;

ANTIOXIDANT ACTIVITY; ARTICLE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; DISULFIDE BOND; DRUG MECHANISM; DRUG TARGETING; DRUG TREATMENT FAILURE; GENE CONTROL; HUMAN; INFLAMMATION; NONHUMAN; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; PROTEIN PROCESSING; PROTEIN SECRETION; REPERFUSION INJURY; SCAVENGING SYSTEM; VASCULAR DISEASE; ANIMAL; DRUG DELIVERY SYSTEM; DRUG EFFECT; METABOLISM; PATHOPHYSIOLOGY; REVIEW;

ANIMALS; ANTIOXIDANTS; CARDIOVASCULAR DISEASES; CEREBROVASCULAR DISORDERS; DRUG DELIVERY SYSTEMS; HUMANS; OXIDATION-REDUCTION; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; THIOREDOXINS;

EID: 60549083680     PISSN: 1871529X     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152908786786179     Document Type: Article

References (55)

1. Griendling, K.K.; FitzGerald, G.A. Oxidative stress and cardiovascular injury: Part I: basic mechanisms and in vivo monitoring of ROS. Circulation, 2003, 108, 1912-1916.
2. Griendling, K.K.; FitzGerald, G.A. Oxidative stress and cardiovascular injury: Part II: animal and human studies. Circulation, 2003, 108, 2034-2040.
3. Berk, B.C. Novel approaches to treat oxidative stress and cardiovascular diseases. Trans. Am. Clin. Climatol. Assoc., 2007, 118, 209-214.
4. Cai, H.; Harrison, D.G. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ. Res., 2000, 87, 840-844.
5. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20, 536 high-risk individuals: a randomised placebo-controlled trial. Lancet, 2002, 360, 23-33.
6. Arner, E.S.; Holmgren, A. Physiological functions of thioredoxin and thioredoxin reductase. Eur. J. Biochem., 2000, 267, 6102-6109.
7. Lillig, C.H.; Holmgren, A. Thioredoxin and related molecules - from biology to health and disease. Antioxid. Redox. Signal., 2007, 9, 25-47.
8. Holmgren, A. Thioredoxin. Annu. Rev. Biochem., 1985, 54, 237-271.
9. Watson, W.H.; Pohl, J.; Montfort, W.R.; Stuchlik, O.; Reed, M.S.; Powis, G.; Jones, D.P. Redox potential of human thioredoxin 1 and identification of a second dithiol/disulfide motif. J. Biol. Chem., 2003, 278, 33408-33415.
10. Chae, H.Z.; Chung, S.J.; Rhee, S.G. Thioredoxin-dependent peroxide reductase from yeast. J. Biol. Chem., 1994, 269, 27670-27678.
11. Kang, S.W.; Chae, H.Z.; Seo, M.S.; Kim, K.; Baines, I.C.; Rhee, S.G. Mammalian peroxiredoxin isoforms can reduce hydrogen peroxide generated in response to growth factors and tumor necrosis factor-alpha. J. Biol. Chem., 1998, 273, 6297-6302.
12. Pekkari, K.; Holmgren, A. Truncated thioredoxin: physiological functions and mechanism. Antioxid. Redox. Signal., 2004, 6, 53-61.
13. Haendeler, J.; Hoffmann, J.; Tischler V.; Berk B.C.; Zeiher A.M.; Dimmeler S. Redox regulatory and anti-apoptotic functions of thioredoxin depend on S-nitrosylation at cysteine 69. Nat. Cell Biol., 2002, 4, 743-749.
14. Haendeler, J.; Hoffmann, J.; Zeiher, A.M.; Dimmeler, S. Antioxidant effects of statins via S-nitrosylation and activation of thioredoxin in endothelial cells: a novel vasculoprotective function of statins. Circulation, 2004, 110, 856-861.
15. Casagrande, S.; Bonetto, V.; Fratelli, M.; Gianazza, E.; Eberini, I.; Massignan, T.; Salmona, M.; Chang, G.; Holmgren, A.; Ghezzi, P. Glutathionylation of human thioredoxin: a possible crosstalk between the glutathione and thioredoxin systems. Proc. Natl. Acad. Sci. USA, 2002, 99, 9745-9749.
16. Taniguchi, Y.; Taniguchi-Ueda, Y.; Mori, K.; Yodoi, J. A novel promoter sequence is involved in the oxidative stress-induced expression of the adult T-cell leukemia-derived factor (ADF)/human thioredoxin (Trx) gene. Nucleic. Acids. Res., 1996, 24, 2746-2752.
17. Billiet, L.; Furman, C.; Larigauderie, G.; Copin, C.; Page, S.; Fruchart, J.C.; Brand, K.; Rouis, M. Enhanced VDUP-1 gene expression by PPARgamma agonist induces apoptosis in human macrophage. J. Cell. Physiol., 2008, 214, 183-191.
18. Spyrou, G.; Enmark, E.; Miranda-Vizuete, A.; Gustafsson, J. Cloning and expression of a novel mammalian thioredoxin. J. Biol. Chem., 1997, 272, 2936-2941.
19. Tanaka, T.; Hosoi, F.; Yamaguchi-Iwai, Y.; Nakamura, H.; Masutani, H.; Ueda, S.; Nishiyama, A.; Takeda, S.; Wada, H.; Spyrou, G.; Yodoi, J. Thioredoxin-2 (TRX-2) is an essential gene regulating mitochondria-dependent apoptosis. EMBO J., 2002, 21, 1695-1703.
20. Nonn, L.; Williams, R.R.; Erickson, R.P.; Powis, G. The absence of mitochondrial thioredoxin 2 causes massive apoptosis, exencephaly, and early embryonic lethality in homozygous mice. Mol. Cell. Biol., 2003, 23, 916-922.
21. Matsuo, Y.; Akiyama, N.; Nakamura, H.; Yodoi, J.; Noda, M.; Kizaka-Kondoh, S. Identification of a novel thioredoxin-related transmembrane protein. J. Biol. Chem., 2001, 276, 10032-10038.
22. Matsuo, Y.; Nishinaka, Y.; Suzuki, S.; Kojima, M.; Kizaka-Kondoh, S.; Kondo, N.; Son, A.; Sakakura-Nishiyama, J.; Yamaguchi, Y.; Masutani, H.; Ishii, Y.; Yodoi, J. TMX, a human transmembrane oxidoreductase of the thioredoxin family: the possible role in disulfide-linked protein folding in the endoplasmic reticulum. Arch. Biochem. Biophys., 2004, 423, 81-87.
23. Holmgren, A. Thioredoxin and glutaredoxin systems. J. Biol. Chem., 1989, 264, 13963-13966.
24. Huber, H.E.; Tabor, S.; Richardson, C.C. Escherichia coli thioredoxin stabilizes complexes of bacteriophage T7 DNA polymerase and primed templates. J. Biol. Chem., 1987, 262, 16224-16232.
25. Lillig, C.H.; Prior, A.; Schwenn, J.D.; Aslund, F.; Ritz, D.; Vlamis-Gardikas, A.; Holmgren, A. New thioredoxins and glutaredoxins as electron donors of 3'′-phosphoadenylylsulfate reductase. J. Biol. Chem., 1999, 274, 7695-7698.
26. Hirota, K.; Matsui, M.; Iwata, S.; Nishiyama, A.; Mori, K.; Yodoi, J. AP-1 transcriptional activity is regulated by a direct association between thioredoxin and Ref-1. Proc. Natl. Acad. Sci. USA, 1997, 94, 3633-3638.
27. Hirota, K.; Murata, M.; Sachi, Y.; Nakamura, H.; Takeuchi, J.; Mori, K.; Yodoi, J. Distinct roles of thioredoxin in the cytoplasm and in the nucleus. A two-step mechanism of redox regulation of transcription factor NF-kappaB. J. Biol. Chem., 1999, 274, 27891-27897.
28. Ueno, M.; Masutani, H.; Arai, R.J.; Yamauchi, A.; Hirota, K.; Sakai, T.; Inamoto, T.; Yamaoka, Y.; Yodoi, J.; Nikaido, T. Thioredoxin-dependent redox regulation of p53-mediated p21 activation. J. Biol. Chem., 1999, 274, 35809-35815.
29. Ueda, S.; Masutani, H.; Nakamura, H.; Tanaka, T.; Ueno, M.; Yodoi, J. Redox control of cell death. Antioxid. Redox. Signal., 2002, 4, 405-414.
30. Meuillet, E.J.; Mahadevan, D.; Berggren, M.; Coon, A.; Powis, G. Thioredoxin-1 binds to the C2 domain of PTEN inhibiting PTEN's lipid phosphatase activity and membrane binding: a mechanism for the functional loss of PTEN's tumor suppressor activity. Arch. Biochem. Biophys., 2004, 429, 123-133.
31. Nishiyama, A.; Matsui, M.; Iwata, S.; Hirota, K.; Masutani, H.; Nakamura, H.; Takagi, Y.; Sono, H.; Gon, Y.; Yodoi, J. Identification of thioredoxin-binding protein-2/vitamin D(3) up-regulated protein 1 as a negative regulator of thioredoxin function and expression. J. Biol. Chem., 1999, 274, 21645-21650.
32. Junn, E.; Han, S.H.; Im, J.Y.; Yang, Y.; Cho, E.W.; Um, H.D.; Kim, D.K.; Lee, K.W.; Han, P.L.; Rhee, S.G.; Choi, I. Vitamin D3 up-regulated protein 1 mediates oxidative stress via suppressing the thioredoxin function. J. Immunol., 2000, 164, 6287-6295.
33. Kondo, N.; Ishii, Y.; Kwon, Y.W.; Tanito, M.; Horita, H.; Nishinaka, Y.; Nakamura, H.; Yodoi, J. Redox-sensing release of human thioredoxin from T lymphocytes with negative feedback loops. J. Immunol., 2004, 172, 442-448.
34. Nishinaka, Y.; Nishiyama, A.; Masutani, H.; Oka, S.; Ahsan, K.M.; Nakayama, Y.; Ishii, Y.; Nakamura, H.; Maeda, M.; Yodoi, J. Loss of thioredoxin-binding protein-2/vitamin D3 up-regulated protein 1 in human T-cell leukemia virus type I-dependent T-cell transformation: implications for adult T-cell leukemia leukemogenesis. Cancer Res., 2004, 64, 1287-1292.
35. Yoshida, T.; Oka, S.; Masutani, H.; Nakamura, H.; Yodoi, J. The role of thioredoxin in the aging process: involvement of oxidative stress. Antioxid. Redox. Signal., 2003, 5, 563-570.
36. Bodnar, J.S.; Chatterjee, A.; Castellani, L.W.; Ross, D.A.; Ohmen, J.; Cavalcoli, J.; Wu, C.; Dains, K.M.; Catanese, J.; Chu, M.; Sheth, S.S.; Charugundla, K.; Demant, P.; West, D.B.; de Jong, P.; Lusis, A.J. Positional cloning of the combined hyperlipidemia gene Hyplip1. Nat. Genet., 2002, 30, 110-116.
37. Nakamura, H.; Herzenberg, L.A.; Bai, J.; Araya, S.; Kondo, N.; Nishinaka, Y.; Herzenberg, L.A.; Yodoi, J. Circulating thioredoxin suppresses lipopolysaccharide-induced neutrophil chemotaxis. Proc. Natl. Acad. Sci. USA, 2001, 98, 15143-15148.
38. Nakamura, H.; Masutani, H.; Yodoi, J. Redox imbalance and its control in HIV infection. Antioxid. Redox. Signal., 2002, 4, 455-464.
39. Mahmood, S.; Kawanaka, M.; Kamei, A.; Izumi, A.; Nakata, K.; Niiyama, G.; Ikeda, H.; Hanano, S.; Suehiro, M.; Togawa, K.; Yamada, G. Immunohistochemical evaluation of oxidative stress markers in chronic hepatitis C. Antioxid. Redox. Signal., 2004, 6, 19-24.
40. Sumida, Y.; Nakashima, T.; Yoh, T.; Nakajima, Y.; Ishikawa, H.; Mitsuyoshi, H.; Sakamoto, Y.; Okanoue, T.; Kashima, K.; Nakamura, H.; Yodoi, J. Serum thioredoxin levels as an indicator of oxidative stress in patients with hepatitis C virus infection. J. Hepatol., 2000, 33, 616-622.
41. Sumida, Y.; Nakashima, T.; Yoh, T.; Furutani, M.; Hirohama, A.; Kakisaka, Y.; Nakajima, Y.; Ishikawa, H.; Mitsuyoshi, H.; Okanoue, T.; Kashima, K.; Nakamura, H.; Yodoi, J. Serum thioredoxin levels as a predictor of steatohepatitis in patients with nonalcoholic fatty liver disease. J. Hepatol., 2003, 38, 32-38.
42. Yoshida, S.; Katoh, T.; Tetsuka, T.; Uno, K.; Matsui, N.; Okamoto, T. Involvement of thioredoxin in rheumatoid arthritis: its costimulatory roles in the TNF-alpha-induced production of IL-6 and IL-8 from cultured synovial fibroblasts. J. Immunol., 1999, 163, 351-358.
43. Yamawaki, H.; Haendeler, J.; Berk, B.C. Thioredoxin: a key regulator of cardiovascular homeostasis. Circ. Res., 2003, 93, 1029-1033.
44. Miwa, K.; Kishimoto, C.; Nakamura, H.; Makita, T.; Ishii, K.; Okuda, N.; Yodoi, J.; Sasayama, S. Serum thioredoxin and alphatocopherol concentrations in patients with major risk factors. Circ. J., 2005, 69, 291-294.
45. Yokomise, H.; Fukuse, T.; Hirata, T.; Ohkubo, K.; Go, T.; Muro, K.; Yagi, K.; Inui, K.; Hitomi, S.; Mitsui, A.; Hirakawa, T.; Yodoi, J.; Wada, H. Effect of recombinant human adult T cell leukemia-derived factor on rat lung reperfusion injury. Respiration, 1994, 61, 99-104.
46. Okubo, K.; Kosaka, S.; Isowa, N.; Hirata, T.; Hitomi, S.; Yodoi, J.; Nakano, M.; Wada, H. Amelioration of ischemia-reperfusion injury by human thioredoxin in rabbit lung. J. Thorac. Cardiovasc. Surg., 1997, 113, 1-9.
47. Nakamura, H.; De Rosa, S.C.; Yodoi, J.; Holmgren, A.; Ghezzi, P.; Herzenberg, L.A.; Herzenberg, L.A. Chronic elevation of plasma thioredoxin: inhibition of chemotaxis and curtailment of life expectancy in AIDS. Proc. Natl. Acad. Sci. USA, 2001, 98, 2688-2693.
48. Takagi, Y.; Mitsui, A.; Nishiyama, A.; Nozaki, K.; Sono, H.; Gon, Y.; Hashimoto, N.; Yodoi, J. Overexpression of thioredoxin in transgenic mice attenuates focal ischemic brain damage. Proc. Natl. Acad. Sci. USA, 1999, 96, 4131-4136.
49. Mitsui, A.; Hamuro, J.; Nakamura, H.; Kondo, N.; Hirabayashi, Y.; Ishizaki-Koizumi, S.; Hirakawa, T.; Inoue, T.; Yodoi, J. Overexpression of human thioredoxin in transgenic mice controls oxidative stress and life span. Antioxid. Redox. Signal., 2002, 4, 693-696.
50. Tanito, M.; Masutani, H.; Nakamura, H.; Oka, S.; Ohira, A.; Yodoi, J. Attenuation of retinal photooxidative damage in thioredoxin transgenic mice. Neurosci. Lett., 2002, 326, 142-146.
51. Shioji, K.; Kishimoto, C.; Nakamura, H.; Masutani, H.; Yuan, Z.; Oka, S.; Yodoi, J. Overexpression of thioredoxin-1 in transgenic mice attenuates adriamycin-induced cardiotoxicity. Circulation, 2002, 106, 1403-1409.
52. Hoshino, T.; Nakamura, H.; Okamoto, M.; Kato, S.; Araya, S.; Nomiyama, K.; Oizumi, K.; Young, H.A.; Aizawa, H.; Yodoi, J. Redox-active protein thioredoxin prevents proinflammatory cytokine- or bleomycin-induced lung injury. Am. J. Respir. Crit. Care Med., 2003, 168, 1075-1083.
53. Nakamura, H.; Tamura, S.; Watanabe, I.; Iwasaki, T.; Yodoi, J. Enhanced resistancy of thioredoxin-transgenic mice against influenza virus-induced pneumonia. Immunol. Lett., 2002, 82, 165-170.
54. Takagi, Y.; Gon, Y.; Todaka, T.; Nozaki, K.; Nishiyama, A.; Sono, H.; Hashimoto, N.; Kikuchi, H.; Yodoi, J. Expression of thioredoxin is enhanced in atherosclerotic plaques and during neointima formation in rat arteries. Lab. Invest., 1998, 78, 957-966.
55. Yamawaki, H.; Berk, B.C. Thioredoxin: a multifunctional antioxidant enzyme in kidney, heart and vessels. Curr. Opin. Nephrol. Hypertens., 2005, 14, 149-153.